Balchem Corporation (BCPC) AI Stock Analysis

Balchem Corporation, headquartered in New Hampton, New York, develops, manufactures, and markets specialty performance ingredients and products. The company operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Human Nutrition & Health supplies ingredients to the food and beverage industry, including spray dried powders, lipid systems, flavor delivery systems, choline nutrients, and mineral amino acid chelates, alongside microencapsulation technologies. Animal Nutrition & Health provides microencapsulated products, chelation technology, and essential nutrients such as choline chloride for livestock and companion animals. Specialty Products offers ethylene oxide for medical device sterilization, propylene oxide for agricultural fumigation, and chelated minerals for high-value crop nutrition.

Balchem recorded a 5-year revenue CAGR of 8.1% from FY2020 to FY2025. Annual revenue grew from $799.0M in FY2021 to $942.4M in FY2022, declined to $922.4M in FY2023, and increased to $953.7M in FY2024 and $1.04B in FY2025. Gross margin expanded from 30.4% in FY2021 to 35.7% in FY2025, while operating margin rose from 16.0% to 21.1%. Net income reached $154.8M in FY2025, up from $96.1M in FY2021, with diluted EPS rising from $3.57 to $5.15. Trailing twelve month revenue was $1.09B with an operating margin of 20.8%. In the quarter ended June 30, 2026, revenue increased 11.2% year-over-year and earnings grew 18.8%.

As of June 30, 2026, Balchem held $63.2M in cash and short-term investments alongside total debt of $166.7M, resulting in net debt of $103.5M. Total assets were $1.69B against shareholders' equity of $1.30B, with a current ratio of 2.66 and a debt-to-equity ratio of 0.13. For FY2025, operating cash flow stood at $216.6M and capital expenditures were $43.5M, generating free cash flow of $173.1M. Cash deployment in FY2025 included $107.6M in share buybacks and $28.3M in dividends paid.

At a closing price of $170.73, Balchem has a market capitalization of $5.44B and an enterprise value of $5.47B. Its trailing P/E of 33.6x and forward P/E of 29.3x trade at a premium to the median of its US-listed Basic Materials peers, which stand at 19.7x and 13.4x, respectively. The company's EV/EBITDA of 20.3x and price-to-sales of 5.0x also compare to peer medians of 10.5x and 1.8x. Over the trailing 1-year period, BCPC returned 18.0%, exceeding the S&P 500 return of 16.8%, while its 5-year return of 16.1% trailed the S&P 500 return of 83.0%.

Balchem pays an annual forward dividend of $0.96 per share, yielding 0.56% with a payout ratio of 17.5%. The company has paid dividends for 40 consecutive years and achieved a 5-year annualized dividend growth rate of 10.6%. Its last ex-dividend date was December 23, 2025.

Wall Street consensus includes 1 Strong Buy, 1 Buy, and 1 Hold rating. The mean price target of $209.25 represents a 22.6% premium to the last closing price of $170.73. For the fiscal year ending December 31, 2026, analysts estimate EPS of $5.84 on revenue of $1.13B. For the subsequent fiscal year, 3 analysts project EPS of $6.27 and revenue of $1.20B. Balchem beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is October 23, 2026.

This page is an AI-written research summary of Balchem Corporation (BCPC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BCPC income statement, BCPC balance sheet, BCPC key metrics, BCPC analyst forecast, BCPC chart. See the BCPC stock overview for the latest quote and news.